AGP Picks
View all

Tecentriq market seen rising to $7.65M by 2030

Nov. 12, 2026
Tecentriq market seen rising to $7.65M by 2030
By AI, Created 17:15 UTC, Nov 12, 2026, AGP -

The Business Research Company says the global Tecentriq (atezolizumab) market is growing on rising cancer rates, wider use of immunotherapy and expanding oncology investment. The report projects the market will rise from $4.36 million in 2025 to $7.65 million by 2030, with North America leading now and Asia-Pacific expected to grow fastest.

Why it matters: - Tecentriq's market growth signals continued demand for immunotherapy in cancer care as hospitals and oncologists shift away from reliance on traditional chemotherapy alone. - The report links future expansion to higher screening rates, more oncology clinical trials, biomarker-based treatment adoption and improved patient survival. - The market outlook matters for drugmakers, oncology providers and investors tracking where cancer-treatment spending is moving.

What happened: - The Business Research Company released a 2026 report on the global Tecentriq (atezolizumab) market. - The report estimates the market will grow from $4.36 million in 2025 to $4.89 million in 2026. - The report projects the market will reach $7.65 million by 2030. - The report cites a 12.2% CAGR for 2025-2026 and an 11.8% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing regional market over the coming years.

The details: - Tecentriq is an immunotherapy drug classified as a monoclonal antibody that targets PD-L1. - The drug blocks the interaction between PD-L1 on tumor and immune cells and PD-1 or B7.1 receptors on T-cells. - That blockade helps reactivate the immune system's ability to recognize and attack cancer cells. - The report says market growth is being driven by the limitations of conventional chemotherapy, approvals of breakthrough immunotherapies, rising cancer incidence and clinical success for PD-L1 inhibitors. - The report says growth is also supported by the dominance of hospital-centered oncology care. - The report says cancer prevalence is rising globally because of an aging population, improved detection, lifestyle factors, environmental influences and longer survival. - The American Cancer Society reported in January 2024 that US cancer cases rose to 2,001,140 from 1,958,310 in 2023, a 2.19% increase. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report includes a free sample download and a full report page. More information - The full market report is available online. The full report

Between the lines: - The report frames Tecentriq as part of a broader oncology market moving toward biomarker-based and immune-based treatments. - The regional split suggests mature adoption in North America and faster upside in markets still building access to cancer diagnostics and treatment. - The added analytics tools point to a report aimed at buyers, strategists and market watchers rather than general consumers.

What's next: - The market is expected to continue expanding through 2030 if cancer incidence, clinical adoption and healthcare investment keep rising. - Asia-Pacific's growth rate will be a key indicator of how quickly immunotherapy penetration broadens beyond established markets. - The report's forecast implies continued interest in PD-L1 inhibitors as cancer care evolves.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.